AG-EE 623 ZW
Categorie
AG-EE 623 ZW Les marques, AG-EE 623 ZW Analogs
AG-EE 623 ZW Les marques melange
AG-EE 623 ZW Formule chimique
C27H36N2O4
AG-EE 623 ZW RX lien
http://www.rxlist.com/cgi/generic/prandin.htm
AG-EE 623 ZW FDA fiche
AG-EE 623 ZW msds (fiche de securite des materiaux)
AG-EE 623 ZW Synthese de reference
W. Grell et al. Int PCT. pat. Appl. WO 93 00 337
AG-EE 623 ZW Poids moleculaire
452.586 g/mol
AG-EE 623 ZW Point de fusion
130-131 oC
AG-EE 623 ZW H2O Solubilite
Aucune information disponible
AG-EE 623 ZW Etat
Solid
AG-EE 623 ZW LogP
5.798
AG-EE 623 ZW Formes pharmaceutiques
Tablet
AG-EE 623 ZW Indication
Pour le traitement du diabète de type II.
AG-EE 623 ZW Pharmacologie
Le répaglinide est un sang hypoglycémiants oraux médicaments de la classe méglitinide utilisés dans la gestion du diabète de type 2 (aussi appelé diabète non insulino-dépendants sucré ou DNID). Le répaglinide abaisse la glycémie en stimulant la libération d'insuline par le pancréas. Cette action dépend de fonctionnement des cellules bêta des îlots pancréatiques. Libération d'insuline glucose-dépendante est et diminue à des concentrations de glucose faible.
AG-EE 623 ZW Absorption
Rapide (biodisponibilité est de 56%)
AG-EE 623 ZW Toxicite
DL50> 1 g / kg (rat) (W. Grell)
AG-EE 623 ZW Information pour les patients
PATIENT INFORMATION
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
AG-EE 623 ZW Organismes affectes
Les humains et autres mammifères
